Recently, according to report, Sweet Chemistry has secured $1 million in funding as investors increasingly seek science-driven opportunities in the fast-growing peptide skincare segment. The round was led by Sandbridge Capital, with participation from industry investors including Top Knot Ventures’ Manica Blain, No Other Ventures’ Charles Chase, Vegamour CMO Michelle Miller, and Sonoma Brands Capital’s managing director Kevin Murphy.
Founded by chemist and former Nars executive Alec Batis, Sweet Chemistry introduces Matrikynes, a proprietary class of polypeptides known as matrikines, developed from a decade of regenerative medicine research by its parent company, Xylyx Bio. Derived from upcycled bovine bone, these peptides contain over 300 extracellular matrix polypeptides shown in clinical trials to significantly improve skin structure and appearance.
The funding will support marketing, product development, and new hires as the brand eyes an additional $1.5 million to $3 million raise. Sweet Chemistry debuted at Violet Grey last month and plans further retail expansion in 2026. Its current four-product lineup—priced between $148 and $170—is projected to generate $1 million in sales this year and up to $4 million in 2026.
Sweet Chemistry’s emergence aligns with a wider investor shift toward biotech-backed skincare. Global Growth Insights values the peptide skincare market at $2.3 billion in 2024, expected to grow to $6.6 billion by 2033. Batis plans to build the brand into a comprehensive skincare ecosystem, with a 10-year roadmap to expand into 42 products across hydration, treatment, and nourishment categories.
